1 Du, X. et al. Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice. Cell Res 28, 433-447, doi:10.1038/s41422-018-0012-z (2018).2 Du, X. et al. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy. Cell Res 28, 416-432, doi:10.1038/s41422-018-0011-0 (2018).3 Zhang, Y. et al. Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy. Cell Res 29, 609-627, doi:10.1038/s41422-019-0184-1 (2019).4 Liu, M. et al. CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect. Signal Transduct Target Ther7, 224, doi:10.1038/s41392-022-01030-x (2022).5 Liu, M. et al. Soluble CTLA-4 mutants ameliorate immune-related adverse events but preserve efficacy of CTLA-4- and PD-1-targeted immunotherapy. Sci Transl Med 15, eabm5663, doi:10.1126/scitranslmed.abm5663 (2023).6 Salem, J. E. et al. Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis.N Engl J Med 380, 2377-2379, doi:10.1056/NEJMc1901677 (2019).7 Wei, S. C. et al. A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention. Cancer Discov 11, 614-625, doi:10.1158/2159-8290.CD-20-0856 (2021).